Infliximab for Injection
Efficacy and safety are equivalent to the original drug (Johnson & Johnson/Merck & Co.
The first infliximab biosimilar marketed in China
Infliximab for Injection (Reminton), a recombinant anti-TNF-alpha chimeric monoclonal antibody, was approved for marketing by the National Medical Products Administration (NMPA) on July 14, 2021. It is the first infliximab biosimilar marketed in China. Taking advantage of CHO cell expression system, Remin_x005f ton has been proved with good efficacy, better safety, and lower immunogenicity in clinical studies.
Indications:
Crohn's disease in adults and children over 6 years of age, stulizing Crohn's disease,
ulcerative colitis in adults, ankylosing spondylitis, rheumatoid arthritis, and psoriasis.
Recommended reading
Related products
-
Quick View
Phasellus varius turpis
Original price was: $87.00.$76.00Current price is: $76.00.Add to cartFusce nec diam et dolor ornare rhoncus nec ut mauris. In eleifend mi in felis dictum fermentum. Morbi vel arcu sit amet dolor venenatis bibendum in eu dui. Nulla velit dolor, imperdiet consectetur luctus ut, faucibus eget est.
-
Quick View
Fusce congue cursus metus
$88.00Add to cartNulla feugiat felis tempor sem finibus egestas. Maecenas est nunc, faucibus in tristique nec, ornare et tortor. Mauris maximus lectus vel metus finibus, eget ullamcorper leo auctor. Donec at interdum nibh, in blandit massa. Nam pulvinar mollis quam
-
Quick View
Aenean non pellentesque mauris
Original price was: $68.00.$55.00Current price is: $55.00.Add to cartNullam porttitor pharetra ullamcorper. Praesent varius erat vitae nibh laoreet cursus. Donec suscipit gravida viverra. Suspendisse consectetur ipsum augue, a varius enim tempus a. Phasellus id nibh arcu. Curabitur rutrum vehicula mi id congue. Phasellus vitae leo sodales, pretium turpis non, efficitur eros. Donec fermentum at nisi suscipit vulputate.
-
Quick View
Aliquam id quam elementum arcu eleifend
$44.00Add to cartAenean bibendum posuere neque, quis hendrerit libero ultrices lacinia. Vestibulum venenatis elit non bibendum pulvinar. In luctus urna sapien, posuere fermentum nunc tempus eget. Fusce hendrerit nec diam quis ornare. Duis auctor, libero in efficitur finibus, purus diam maximus est, et rhoncus sapien justo nec sem
Reviews
There are no reviews yet.